Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.

Ho WS, Wang H, Maggio D, Kovach JS, Zhang Q, Song Q, Marincola FM, Heiss JD, Gilbert MR, Lu R, Zhuang Z.

Nat Commun. 2018 May 29;9(1):2126. doi: 10.1038/s41467-018-04425-z.

2.

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.

Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS, Johnson F, Kovach JS.

Clin Cancer Res. 2017 Jul 1;23(13):3277-3284. doi: 10.1158/1078-0432.CCR-16-2299. Epub 2016 Dec 30.

3.

The relationship between body iron stores and blood and urine cadmium concentrations in US never-smoking, non-pregnant women aged 20-49 years.

Gallagher CM, Chen JJ, Kovach JS.

Environ Res. 2011 Jul;111(5):702-7. doi: 10.1016/j.envres.2011.03.007. Epub 2011 Apr 19.

PMID:
21507392
4.

Environmental cadmium and breast cancer risk.

Gallagher CM, Chen JJ, Kovach JS.

Aging (Albany NY). 2010 Nov;2(11):804-14.

5.

A comparison of multisensory and traditional interventions on inpatient psychiatry and geriatric neuropsychiatry units.

Knight M, Adkison L, Kovach JS.

J Psychosoc Nurs Ment Health Serv. 2010 Jan;48(1):24-31. doi: 10.3928/02793695-20091204-03.

PMID:
20102130
6.

Cadmium, follicle-stimulating hormone, and effects on bone in women age 42-60 years, NHANES III.

Gallagher CM, Moonga BS, Kovach JS.

Environ Res. 2010 Jan;110(1):105-11. doi: 10.1016/j.envres.2009.09.012.

PMID:
19875111
8.

Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms.

Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, Lonser R, Zhuang Z.

Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11697-702. doi: 10.1073/pnas.0905930106. Epub 2009 Jun 29. Erratum in: Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14734.

9.

Urinary cadmium and osteoporosis in U.S. Women >or= 50 years of age: NHANES 1988-1994 and 1999-2004.

Gallagher CM, Kovach JS, Meliker JR.

Environ Health Perspect. 2008 Oct;116(10):1338-43. doi: 10.1289/ehp.11452. Epub 2008 Jun 13.

10.

Detection of cancer-specific markers amid massive mass spectral data.

Zhu W, Wang X, Ma Y, Rao M, Glimm J, Kovach JS.

Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14666-71. Epub 2003 Dec 1.

11.

Low frequency of p53 gene mutations in breast cancers of Japanese-American women.

Buzin CH, Tang SH, Cunningham JM, Shibata A, Ross RK, Hartmann A, Blaszyk H, Kovach JS.

Nutr Cancer. 2001;39(1):72-7.

PMID:
11588905
12.

A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome.

Blaszyk H, Hartmann A, Cunningham JM, Schaid D, Wold LE, Kovach JS, Sommer SS.

Int J Cancer. 2000 Jan 20;89(1):32-8.

13.

Clinical cancer research in a managed-care environment.

Kovach JS.

Cancer Invest. 1998;16(5):350-2. No abstract available.

PMID:
9627683
14.

Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer.

Reid JM, Kovach JS, O'Connell MJ, Bagniewski PG, Moertel CG.

Cancer Chemother Pharmacol. 1998;41(6):477-84.

PMID:
9554592
15.

Distribution of endogenous tumour necrosis factor alpha in gliomas.

Maruno M, Kovach JS, Kelly PJ, Yanagihara T.

J Clin Pathol. 1997 Jul;50(7):559-62.

16.

The molecular epidemiology of p53 gene mutations in human breast cancer.

Hartmann A, Blaszyk H, Kovach JS, Sommer SS.

Trends Genet. 1997 Jan;13(1):27-33. Review.

PMID:
9009845
17.

Molecular epidemiology of breast cancers in northern and southern Japan: the frequency, clustering, and patterns of p53 gene mutations differ among these two low-risk populations.

Blaszyk H, Hartmann A, Tamura Y, Saitoh S, Cunningham JM, McGovern RM, Schroeder JJ, Schaid DJ, Ii K, Monden Y, Morimoto T, Komaki K, Sasa M, Hirata K, Okazaki M, Kovach JS, Sommer SS.

Oncogene. 1996 Nov 21;13(10):2159-66.

PMID:
8950983
18.

Need for standardization of cancer practice via nationally accepted treatment guidelines.

Kovach JS.

Oncology (Williston Park). 1996 Nov;10(11 Suppl):41-3.

PMID:
8953595
19.

Evidence for diverse mutagens in breast cancer.

Blaszyk H, Hartmann A, Liao DZ, Kovach JS, Sommer SS.

Lancet. 1996 Sep 7;348(9028):683-4. No abstract available.

PMID:
8782770
20.

Overexpression and mutations of p53 in metastatic malignant melanomas.

Hartmann A, Blaszyk H, Cunningham JS, McGovern RM, Schroeder JS, Helander SD, Pittelkow MR, Sommer SS, Kovach JS.

Int J Cancer. 1996 Jul 29;67(3):313-7.

21.

A polymorphism but no mutations in the GADD45 gene in breast cancers.

Blaszyk H, Hartmann A, Sommer SS, Kovach JS.

Hum Genet. 1996 Apr;97(4):543-7.

PMID:
8834260
22.

High frequency of p53 gene mutations in primary breast cancers in Japanese women, a low-incidence population.

Hartmann A, Blaszyk H, Saitoh S, Tsushima K, Tamura Y, Cunningham JM, McGovern RM, Schroeder JJ, Sommer SS, Kovach JS.

Br J Cancer. 1996 Apr;73(8):896-901.

23.

Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value.

Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS.

Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1093-6.

24.

Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses.

De Vries EM, Ricke DO, De Vries TN, Hartmann A, Blaszyk H, Liao D, Soussi T, Kovach JS, Sommer SS.

Hum Mutat. 1996;7(3):202-13.

PMID:
8829653
25.

p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers.

Hartmann A, Blaszyk H, McGovern RM, Schroeder JJ, Cunningham J, De Vries EM, Kovach JS, Sommer SS.

Oncogene. 1995 Feb 16;10(4):681-8.

PMID:
7862445
26.

Rapid and efficient screening for p53 gene mutations by dideoxy fingerprinting.

Blaszyk H, Hartmann A, Schroeder JJ, McGovern RM, Sommer SS, Kovach JS.

Biotechniques. 1995 Feb;18(2):256-60.

PMID:
7727127
27.

Novel pattern of P53 mutation in breast cancers from Austrian women.

Hartmann A, Rosanelli G, Blaszyk H, Cunningham JM, McGovern RM, Schroeder JJ, Schaid DJ, Kovach JS, Sommer SS.

J Clin Invest. 1995 Feb;95(2):686-9. Erratum in: J Clin Invest 1995 Jun;95(6):2991.

28.

p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis.

Cunningham JM, Ingle JN, Jung SH, Cha SS, Wold LE, Farr G, Witzig TE, Krook JE, Wieand HS, Kovach JS.

J Natl Cancer Inst. 1994 Dec 21;86(24):1871-3. No abstract available.

PMID:
7990162
29.

Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer.

Rubin J, Charboneau JW, Reading C, Kovach JS.

Hum Gene Ther. 1994 Nov;5(11):1385-99. No abstract available.

PMID:
7893809
30.

Advanced colorectal adenocarcinoma: treatment with amonafide.

Marschke RF Jr, Wieand HS, O'Connell MJ, Rubin J, Schutt AJ, Burch PA, Kovach JS.

J Natl Cancer Inst. 1994 Jun 15;86(12):944-5. No abstract available.

PMID:
8196086
31.

Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer.

Blaszyk H, Vaughn CB, Hartmann A, McGovern RM, Schroeder JJ, Cunningham J, Schaid D, Sommer SS, Kovach JS.

Lancet. 1994 May 14;343(8907):1195-7.

PMID:
7909871
32.

Detection of p53 antigen expression in cytologic preparations of ovarian carcinomas.

Cheung TK, Cunningham JM, Webb MJ, Goellner JR, Kovach JS.

Anticancer Res. 1994 May-Jun;14(3B):1335-8.

PMID:
8067702
33.

A tandem CC-->TT transition in the p53 gene of a breast cancer.

Blaszyk H, Hartmann A, Wold LE, Schroeder JJ, McGovern RM, Sommer SS, Kovach JS.

Hum Mutat. 1994;4(2):158-60. No abstract available.

PMID:
7981721
34.

all-trans retinoic acid: a dose-seeking study in solid tumors.

Pitot HC 4th, Rubin J, Kovach JS, Schutt AJ, Adamson PC.

Ann N Y Acad Sci. 1993 Dec 31;691:250-2. No abstract available.

PMID:
8129304
35.

Distribution of transforming growth factor-beta 1 in human astrocytomas.

Horst HA, Scheithauer BW, Kelly PJ, Kovach JS.

Hum Pathol. 1992 Nov;23(11):1284-8.

PMID:
1427755
36.

Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis?

O'Connell MJ, Schaid DJ, Ganju V, Cunningham J, Kovach JS, Thibodeau SN.

Cancer. 1992 Sep 15;70(6 Suppl):1732-9.

PMID:
1516028
37.

Expression of p53 and 17p allelic loss in colorectal carcinoma.

Cunningham J, Lust JA, Schaid DJ, Bren GD, Carpenter HA, Rizza E, Kovach JS, Thibodeau SN.

Cancer Res. 1992 Apr 1;52(7):1974-80.

38.
39.

Pattern of p53 gene mutations in breast cancers of women of the midwestern United States.

Sommer SS, Cunningham J, McGovern RM, Saitoh S, Schroeder JJ, Wold LE, Kovach JS.

J Natl Cancer Inst. 1992 Feb 19;84(4):246-52.

PMID:
1734086
40.

Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer.

van Haelst Pisani C, Kovach JS, Kita H, Leiferman KM, Gleich GJ, Silver JE, Dennin R, Abrams JS.

Blood. 1991 Sep 15;78(6):1538-44.

41.

Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinomas.

Kovach JS, McGovern RM, Cassady JD, Swanson SK, Wold LE, Vogelstein B, Sommer SS.

J Natl Cancer Inst. 1991 Jul 17;83(14):1004-9.

PMID:
1712853
42.
43.

Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma.

Patel SR, Kvols LK, Rubin J, O'Connell MJ, Edmonson JH, Ames MM, Kovach JS.

Invest New Drugs. 1991 Feb;9(1):53-7.

PMID:
1709152
44.

Searching for clues to effective use of biologic response modifiers.

Kovach JS.

J Natl Cancer Inst. 1991 Jan 2;83(1):2-3. No abstract available.

PMID:
1878016
45.

Effector function of lymphokine-activated killer cells and cytotoxic T lymphocytes in ovarian epithelial carcinoma.

Lentz SS, Kovach JS, McKean DJ, Wieand HS, Podratz KC.

Gynecol Oncol. 1990 Aug;38(2):191-6.

PMID:
2387535
46.

Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation.

Ames MM, Richardson RL, Kovach JS, Moertel CG, O'Connell MJ.

Cancer Res. 1990 Jan 1;50(1):206-10.

PMID:
2104537
47.

Recycling of tumor necrosis factor-alpha receptor in MCF-7 cells.

Vuk-Pavlović S, Kovach JS.

FASEB J. 1989 Dec;3(14):2633-40.

PMID:
2556313
48.

Computer program for handling investigational oncology drugs.

Burnham NL, Elcombe SA, Skorlinski CR, Kosanke JL, Kovach JS.

Am J Hosp Pharm. 1989 Sep;46(9):1821-4. No abstract available.

PMID:
2801718
49.

Phenotypic and functional characteristics of mononuclear cells in ovarian carcinoma tumors.

Lentz SS, McKean DJ, Kovach JS, Podratz KC.

Gynecol Oncol. 1989 Aug;34(2):136-40.

PMID:
2787770
50.

Cellular pharmacology of fluorinated pyrimidines in vivo in man.

Kovach JS, Beart RW Jr.

Invest New Drugs. 1989 Apr;7(1):13-25. Review.

PMID:
2661480

Supplemental Content

Loading ...
Support Center